- Home
- MIST vs LPTX Comparison
MIST vs LPTX Comparison
Compare MIST & LPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MIST
- LPTX
- Stock Information
- Founded
- MIST 2003
- LPTX 2011
- Country
- MIST Canada
- LPTX United States
- Employees
- MIST N/A
- LPTX N/A
- Industry
- MIST Biotechnology: Pharmaceutical Preparations
- LPTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MIST Health Care
- LPTX Health Care
- Exchange
- MIST Nasdaq
- LPTX Nasdaq
- Market Cap
- MIST 100.3M
- LPTX 99.5M
- IPO Year
- MIST N/A
- LPTX N/A
- Fundamental
- Price
- MIST $1.81
- LPTX $3.06
- Analyst Decision
- MIST Strong Buy
- LPTX Strong Buy
- Analyst Count
- MIST 3
- LPTX 3
- Target Price
- MIST $13.00
- LPTX $7.50
- AVG Volume (30 Days)
- MIST 372.6K
- LPTX 437.3K
- Earning Date
- MIST 11-12-2024
- LPTX 11-13-2024
- Dividend Yield
- MIST N/A
- LPTX N/A
- EPS Growth
- MIST N/A
- LPTX N/A
- EPS
- MIST N/A
- LPTX N/A
- Revenue
- MIST N/A
- LPTX N/A
- Revenue This Year
- MIST N/A
- LPTX N/A
- Revenue Next Year
- MIST N/A
- LPTX N/A
- P/E Ratio
- MIST N/A
- LPTX N/A
- Revenue Growth
- MIST N/A
- LPTX N/A
- 52 Week Low
- MIST $1.12
- LPTX $1.68
- 52 Week High
- MIST $2.93
- LPTX $5.00
- Technical
- Relative Strength Index (RSI)
- MIST 49.60
- LPTX 51.79
- Support Level
- MIST $1.76
- LPTX $2.87
- Resistance Level
- MIST $1.86
- LPTX $3.12
- Average True Range (ATR)
- MIST 0.10
- LPTX 0.28
- MACD
- MIST -0.02
- LPTX 0.02
- Stochastic Oscillator
- MIST 18.93
- LPTX 49.42
About MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular indications. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to terminate episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).
About LPTX Leap Therapeutics Inc.
Leap Therapeutics Inc is in developing targeted antibody therapies for cancer treatment, focusing on inhibiting tumor-promoting pathways, targeting cancer-specific cell surface molecules, and activating the immune system against cancer cells. The company's lead program, DKN-01, targets Dickkopf-related protein 1 (DKK1) and is in clinical trials for esophagogastric, gynecologic, and colorectal cancers. Their second program, FL-301, targets Claudin18.2-expressing cells. Additionally, the company has two preclinical antibody programs, FL-302 and FL-501, aimed at developing transformative cancer treatments. Operating as a single segment, the company's sole focus is on developing innovative drugs to address unmet needs in cancer therapy. .